196 results
Page 6 of 10
8-K
EX-1.1
28nfb9ibvwrk6c91z
16 Feb 11
Discovery Labs Prices $23.5 Million Public Offering of
12:00am
424B5
ttg2t 78aa9upvhqm
15 Feb 11
Prospectus supplement for primary offering
12:00am
8-K
fsfd1uqsx zbu0d5mulf
9 Feb 11
Other Events
12:00am
8-K
EX-99.1
vdf tlxnz7
9 Feb 11
Other Events
12:00am
8-K
EX-99.1
siod2rsg50t
10 Jan 11
Discovery Labs Provides Update Regarding its Program for Surfaxin® U.S. Marketing Authorization
12:00am
8-K
t41aa a370hnjz
10 Jan 11
Discovery Labs Provides Update Regarding its Program for Surfaxin® U.S. Marketing Authorization
12:00am
CORRESP
n1tjy0netxl bll6s
10 Nov 10
Correspondence with SEC
12:00am
8-K
EX-99.1
1gmq3
9 Nov 10
Results of Operations and Financial Condition
12:00am
CORRESP
2elv0krbetzr cb89
8 Nov 10
Correspondence with SEC
12:00am
8-K
EX-99.1
7p4s2q7lv14209z
21 Oct 10
Discovery Labs Appoints W. Thomas Amick as Chief Executive Officer
12:00am
CORRESP
8r7ifg9nj6 ru
1 Oct 10
Correspondence with SEC
12:00am
8-K
EX-1.1
o3yov ew9elriu
17 Jun 10
Discovery Labs Prices $10.0 Million Public Offering of
12:00am
8-K
EX-99.1
p8yk2j7ss
9 Jun 10
Discovery Labs Reports Preliminary Results from Phase 2 Clinical Trial of Surfaxin in Pediatric Acute Respiratory Failure
12:00am
8-K
EX-1.1
9s9cx3jzyzo45zsp8
18 Feb 10
Discovery Labs Prices $16.5 Million Public Offering of
12:00am
8-K
7msyrtdpflvwvpl99k
16 Feb 10
Other Events
12:00am